<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610012</url>
  </required_header>
  <id_info>
    <org_study_id>IOM RCC</org_study_id>
    <nct_id>NCT00610012</nct_id>
  </id_info>
  <brief_title>Tumor Registry of Advanced Renal Cell Carcinoma</brief_title>
  <acronym>RCC-Registry</acronym>
  <official_title>Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitskreis Klinische Studien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bund der Urologen e.G.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to record information of therapy reality of metastatic or
      locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RCC Registry is a prospective, longitudinal, nation wide cohort study that collects data
      on the treatment reality of patients with mRCC. At inclusion, data in patient
      characteristics, comorbidities, tumor characteristics, and previous treatments are collected.
      During the course of observation data on all systemic treatments, radiotherapies, surgeries,
      and outcome are documented. Patients are followed until death or for a maximum of 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2007</start_date>
  <completion_date type="Actual">May 15, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Documentation of therapies</measure>
    <time_frame>9 years, 3 years per patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Documentation of response rate and adverse reactions; development of a numeric prognostic score</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1500</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Practitioners specialized in oncology and urology in Germany
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy

          -  Start of first palliative therapy within 1 year before enrollment of patient to
             registry; since enrollment of 1000 Patients: start of first palliative therapy within
             4 weeks before enrollment

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goebell Peter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Waldkrankenhaus St. Marien, Erlangen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lothar Müller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Onkologie Leer - Emden - Papenburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>iOMEDICO</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>P J G, A M, L M, H J H, M K, S B, N M. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study. Urol Oncol. 2014 Apr;32(3):362-70. doi: 10.1016/j.urolonc.2013.09.009. Epub 2013 Dec 8.</citation>
    <PMID>24321255</PMID>
  </results_reference>
  <results_reference>
    <citation>Goebell PJ, Müller L, Hurtz HJ, Koska M, Busies S, Marschner N. A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study. Clin Genitourin Cancer. 2016 Feb;14(1):63-8. doi: 10.1016/j.clgc.2015.09.004. Epub 2015 Sep 25.</citation>
    <PMID>26520429</PMID>
  </results_reference>
  <results_reference>
    <citation>Marschner N, Staehler M, Müller L, Nusch A, Harde J, Koska M, Jänicke M, Goebell PJ; RCC Registry Group. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry. Clin Genitourin Cancer. 2017 Apr;15(2):e209-e215. doi: 10.1016/j.clgc.2016.08.022. Epub 2016 Sep 8.</citation>
    <PMID>27720164</PMID>
  </results_reference>
  <results_reference>
    <citation>Goebell PJ, Staehler M, Müller L, Nusch A, Scheffler M, Sauer A, von Verschuer U, Tech S, Kruggel L, Jänicke M, Marschner N; RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma). Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry. Clin Genitourin Cancer. 2018 Dec;16(6):e1101-e1115. doi: 10.1016/j.clgc.2018.06.006. Epub 2018 Jun 27.</citation>
    <PMID>30061035</PMID>
  </results_reference>
  <results_reference>
    <citation>Goebell PJ, Müller L, Hübner A, Harich HD, Boller E, Koska M, Jänicke M, Marschner N; RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma). Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry. Urol Oncol. 2018 Oct;36(10):470.e1-470.e9. doi: 10.1016/j.urolonc.2018.07.007. Epub 2018 Aug 18.</citation>
    <PMID>30131294</PMID>
  </results_reference>
  <results_reference>
    <citation>Marschner N, Müller L, Münch A, Blumenstengel K, Hutzschenreuter U, Busies S. Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists. J Oncol Pharm Pract. 2017 Jun;23(4):288-295. doi: 10.1177/1078155216632379. Epub 2016 Feb 22.</citation>
    <PMID>26908232</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Renal Cell Carcinoma</keyword>
  <keyword>MRCC</keyword>
  <keyword>Therapy-reality</keyword>
  <keyword>Observation</keyword>
  <keyword>Registry</keyword>
  <keyword>RCC</keyword>
  <keyword>ARCC</keyword>
  <keyword>Germany</keyword>
  <keyword>Metastatic Renal Cell Carcinoma</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Renal Cell Cancer</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Interferon</keyword>
  <keyword>Interleukin</keyword>
  <keyword>Temsirolimus</keyword>
  <keyword>Pazopanib</keyword>
  <keyword>Cytokines</keyword>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

